\SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company, founded in 2017, has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Notably, its last investment round amounted to €20.00M, which was led by Omnes Capital, Elaia, Mérieux Equity Partners, and Supernova Invest on 22 May 2025. SeqOne is situated in France and operates within the Analytics, Big Data, Biotechnology, and Health Care industries, with a clear focus on advancing personalized medicine through innovative genomic analysis solutions.
SeqOne
From Genome to Personalized Medicine
France
108 employees
Venture round
Total: $43.00M
Analytics, Big Data +2
General Information
France
BounceWatch is an independent company data service, not affiliated with SeqOne. To contact SeqOne, visit seqone.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does SeqOne compare?
A PDF of SeqOne and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting SeqOne soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
France Market
Analytics
About SeqOne
Business keywords: Genomic Medicine, NGS Data Analysis, AI-powered Software, Oncology, Rare Diseases, In Vitro Diagnostic Medical Device, Healthcare Revolution, Precision Medicine, Bioinformatics, Companion Diagnostics, CE IVDR Certified, Molecular Diagnostics, Cloud-based Platform, Genomic Data Transformation, Personalized Medicine
Services & Products
Target Customers
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | €20.00M | 4 |
|
22 May 2025 |
| Series A | €20.00M | 5 |
|
24 Jan 2022 |
| Seed Round | €3.00M | 3 |
|
28 Mar 2019 |
Latest News
View All
SeqOne Alternatives & Competitors
View All Alternatives
A knowledge-based company focused on developing AI-powered Molecular Diagnostics for chronic disease...
Genomic and theranostic company specializing in precision medicine for the treatment of cancer and g...
Empowering rheumatologists with precise diagnostic tools for autoimmune and inflammatory disease man...
FAQ About SeqOne
Source: BounceWatch company record for SeqOne, https://bouncewatch.com/company/seqone, updated 12 February 2026. When citing, please name BounceWatch and link this page.
